CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx Reports Second Quarter 2023 Results https://www.businesswire.com/news/home/20230808569298/en/CareDx-Reports-Second-Quarter-2023-Results

https://hitconsultant.net/2023/07/25/caredx-acquires-medigo/

https://investors.caredx.com/news/news-details/2023/CareDxs-AlloSure-Lung-dd-cfDNA-Testing-Service-Receives-Medicare-Coverage-for-Lung-Transplant-Rejection-Monitoring/default.aspx

https://www.businesswire.com/news/home/20230510005988/en/CareDx-Reports-First-Quarter-2023-Results

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation https://finance.yahoo.com/news/caredx-miromatrix-announce-exclusive-partnership-105500224.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAE0U4MUjtoO1w4LDWZ7q2mibjGxH2qVRJJEoUku1FhXU6lu2fK5W2Tp6tMBCqQaPK824V3vAtcayeZu0na8B4Na8X4tBRsB_E3EpWKI8lx5MMCrfaQ56mayqeQdzrhQlfghnMi_yUTdN4WDUnQnf5y_p1B8LpFO0AoEHwIgB1lDr

https://www.businesswire.com/news/home/20230227005720/en/CareDx-Reports-Fourth-Quarter-and-Full-Year-2022-Results

https://www.businesswire.com/news/home/20230216005360/en/CareDx-Showcases-Latest-Advancements-in-Cellular-Transplant-and-Therapy-Including-Specialized-Digital-Health-Solutions-at-the-2023-Tandem-Meetings

https://www.businesswire.com/news/home/20230109005336/en/CareDx-Reports-Preliminary-Revenue-Results-for-Fourth-Quarter-and-Full-Year-2022

CareDx Announces $50 Million Stock Repurchase Program https://www.stocktitan.net/news/CDNA/care-dx-announces-50-million-stock-repurchase-0ojbl84wccp3.html?s=35

https://www.businesswire.com/news/home/20221111005229/en/CareDx-Committed-to-Delivering-Clinical-Innovation-to-the-Transplant-Patient-and-Physician-Community

CareDx GAAP EPS of -$0.06 beats by $0.33, revenue of $79.4M misses by $3.22M https://seekingalpha.com/news/3901313-caredx-gaap-eps-of-0_06-beats-0_33-revenue-of-79_4m-misses-3_22m • CareDx press release (NASDAQ:CDNA): Q3 GAAP EPS of -$0.06 beats by $0.33. • Revenue of $79.4M (+5.0% Y/Y) misses by $3.22M. • For the full year 2022, CareDx is revising our revenue expectations to be in the range of $320 million to $325 million due to lower Q3 revenue and a higher than anticipated shift in payer mix to commercial payors. • Full year consensus revenue estimate is $327.79M.

CareDx Reports Third Quarter 2022 Results https://www.benzinga.com/pressreleases/22/11/b29555287/caredx-reports-third-quarter-2022-results

https://www.businesswire.com/news/home/20221101005639/en/Independent-Longitudinal-Study-Finds-CareDx%E2%80%99s-AlloSure-Detects-Early-Signs-of-Rejection-in-Pediatric-Kidney-Transplant-Patients

Transplantationspatienten erleben weniger Schmerzen und weniger unerwünschte Ereignisse mit nicht-invasiven Testlösungen von CareDx https://www.businesswire.com/news/home/20220927005427/en/Transplant-Patients-Experience-Less-Pain-and-Fewer-Adverse-Events-with-CareDx-Non-Invasive-Testing-Solutions

CareDx Q2 results miss estimates, co revises FY 2022 revenue guidance https://seekingalpha.com/news/3867475-caredx-q2-results-miss-estimates-co-revises-fy-2022-revenue-guidance • CareDx press release (NASDAQ:CDNA): Q2 Non-GAAP EPS of -$0.13 misses by $0.02. • Revenue of $80.6M (+8.6% Y/Y) misses by $1.25M. • Sees FY 2022 revenue of $325 million to $335 million vs. previous forecast of $330M to $350M. The consensus revenue estimate is $337.96M.